Goldman Sachs Lifts AstraZeneca Price Target Amid Strong Clinical Data
AstraZeneca's stock price rose after Goldman Sachs increased its price target for the pharmaceutical company. The new target of 16,526 pence represents a modest uplift from the previous 16,300 pence and reflects the analysts' incremental confidence in AstraZeneca's medium-term earnings potential.
The stock closed at 122.85 GBP on the London Stock Exchange on September 17, 2026, which is 21.9% below its 52-week high of 157.30 GBP but above its 52-week low of 107.84 GBP. This puts the stock in the middle of its yearly trading band.
The positive data for AstraZeneca's lung drug candidate tozorakimab in chronic obstructive pulmonary disease has strengthened the company's late-stage pipeline and analysts see this as a major opportunity to expand AstraZeneca's respiratory franchise. The recent analyst target increases and favorable clinical data add support to the medium-term narrative.